Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schizophrenia
Launched by PAKISTAN INSTITUTE OF LIVING AND LEARNING · Jun 4, 2019
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to explore new ways to help young adults with early signs of schizophrenia and related disorders. The researchers want to see if adding two specific therapies—Individual Placement and Support (IPS), which helps people find jobs and improve their work skills, and Cognitive Remediation Therapy (CRT), which focuses on improving thinking and memory skills—can be helpful when combined with the usual medication and support these patients receive. The goal is to find out if these additional therapies are practical and acceptable for patients who are just starting to experience these symptoms.
To be part of this study, participants need to be between 18 and 35 years old and have a confirmed diagnosis of schizophrenia or similar conditions. They should also have been stable on their medication for at least four weeks and be in touch with mental health services. Importantly, they should be within five years of their diagnosis and able to understand what it means to take part in the trial. During the study, participants can expect to receive support and therapies designed to help them manage their symptoms and improve their quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male/Female patients aged between 18-35 years.
- • 2. Diagnosis of schizophrenia confirmed by SCID meeting DSM-V criteria for schizophrenia, schizophreniform or schizoaffective psychosis.
- • 3. Stable on medication for the past four weeks.
- • 4. In contact with mental health services
- • 5. Within 5 years of diagnosis.
- • 6. Able to demonstrate the capacity to provide informed consent to take part in this feasibility trial, as assessed by their own clinician.
- Exclusion Criteria:
- • 1. Active DSM-V substance abuse (except nicotine or caffeine) or dependence within the last three months
- • 2. Relevant CNS or other medical disorders
- • 3. Diagnosis of Learning Disability.
About Pakistan Institute Of Living And Learning
The Pakistan Institute of Living and Learning (PILL) is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and evidence-based practices. With a focus on improving mental health and overall well-being, PILL conducts rigorous clinical trials that aim to evaluate new treatments and therapeutic approaches. The institute collaborates with a diverse range of stakeholders, including healthcare professionals, researchers, and community organizations, to ensure the highest standards of ethical conduct and scientific integrity in its studies. PILL is committed to translating research findings into practical solutions that enhance the quality of life for individuals and communities in Pakistan and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials